

BIOGEN IDEC - Diversification and Strong Foothold in MS to Reign

https://marketpublishers.com/r/BE483B376FAEN.html

Date: November 2012

Pages: 4

Price: US\$ 90.00 (Single User License)

ID: BE483B376FAEN

Abstracts

We continue to like Biogen Idec (BIIB) as next year is also going to be eventful: Approval and launch of BG-12 (dimethyl fumerate, under review with FDA & EMEA, est. PDUFA: late Mar. 2013, peak sales potential ww – \$2.5b by 2018) and clinical news flow from its late stage pipeline products. BIIB revised its FY12 sales growth guidance upwards (from mid-single digits to mid to high-single digits) on growing volumes despite growing competition in the MS therapy area. For more details on the upcoming catalysts, please read our report released on 7th Nov. 2012, titled, "Biogen Idec - Diversification and Strong Foothold in MS to Reign".



I would like to order

Product name: BIOGEN IDEC - Diversification and Strong Foothold in MS to Reign

Product link: https://marketpublishers.com/r/BE483B376FAEN.html

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/BE483B376FAEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970